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Abstract
Introduction—This review summarizes the current literature for the prevalence and medical 
costs of noncommunicable chronic diseases among adult Medicaid beneficiaries to inform future 
program design.
Methods—The databases MEDLINE and CINAHL were searched in August 2016 using 
keywords, including Medicaid, health status, and healthcare cost, to identify original studies that 
were published during 2000–2016, examined Medicaid as an independent population group, 
examined prevalence or medical costs of chronic conditions, and included adults within the age 
group 18–64 years. The review and data extraction was conducted in Fall 2016–Spring 2017. 
Disease-related costs (costs specifically to treat the disease) and total costs (all-cause medical 
costs for a patient with the disease) are presented separately.
Results—Among the 29 studies selected, prevalence estimates for enrollees aged 18–64 years 
were 8.8%–11.8% for heart disease, 17.2%–27.4% for hypertension, 16.8%–23.2% for 
hyperlipidemia, 7.5%–12.7% for diabetes, 9.5% for cancer, 7.8%–19.3% for asthma, 5.0%–22.3% 
for depression, and 55.7%–62.1% for one or more chronic conditions. Estimated annual per 
patient disease-related costs (2015 U.S. dollars) were $3,219–$4,674 for diabetes, $3,968–$6,491 
for chronic obstructive pulmonary disease, and $989–$3,069 for asthma. Estimated hypertension-
related costs were $687, but total costs per hypertensive beneficiary ranged much higher. 
Estimated total annual healthcare costs were $29,271–$51,937 per beneficiary with heart failure 
and $11,446–$20,585 per beneficiary with schizophrenia. Costs among beneficiaries with cancer 
were $29,384–$46,194 for the 6 months following diagnosis.
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Conclusions—These findings could help inform the evaluation of interventions to prevent and 
manage noncommunicable chronic diseases and their potential to control costs among the 
vulnerable Medicaid population.
INTRODUCTION
The prevalence of chronic diseases has been high in the U.S. in recent decades.1 In 2012, 
half of all U.S. adults had at least one chronic condition, and at least one in four had two or 
more.2 The high prevalence of chronic diseases is a key driver of total U.S. healthcare costs; 
in 2010, 86% of healthcare spending was for patients with at least one chronic condition, 
and 71% of spending was for patients with multiple conditions.3
Medicaid is the second largest source of health insurance in the U.S., after employer-
provided insurance, and the largest public source of insurance.4,5 In 2012, average monthly 
enrollment in Medicaid was 57.5 million, and total Medicaid program expenditures for that 
year were $428.5 billion.6 Historically, Medicaid has primarily covered low-income children 
and parents, pregnant women, and the disabled.6–8 This population is vulnerable to higher 
rates of chronic diseases than are seen in the U.S. as a whole or even in the low-income 
population overall.9
The Medicaid population has changed and grown substantially since the program began in 
1965.7,8 As the Medicaid population continues to change, it is increasingly important to 
understand the major health burdens this population faces and the associated medical costs, 
which is important for informing future program design and developing health promotion 
programs to contain or reduce the public health burden and healthcare costs. Although the 
literature on the prevalence of, and costs associated with, chronic diseases among adult 
Medicaid beneficiaries has expanded rapidly in recent years, to the authors’ knowledge a 
review article summarizing these findings is not available. This review describes the current 
literature related to the prevalence of chronic diseases and associated medical costs among 
adult Medicaid beneficiaries to inform future program design and interventions to manage 
chronic diseases among this group.
METHODS
Initial scoping determined the literature on chronic disease prevalence and costs among 
Medicaid beneficiaries was too diverse and not large enough for a systematic review and 
meta-analysis; the evidence for each health condition and outcome was limited and too 
heterogeneous. This review serves as an overview by summarizing the current literature 
including all noncommunicable chronic diseases and covering both topic areas of disease 
prevalence and medical costs. Therefore, the authors did not strictly adhere to the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist guidelines 
for this project.
Selection of Literature
The review included peer-reviewed journal articles published between January 2000 and 
August 2016. The databases MEDLINE and CINAHL were searched in August 2016 and 
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the search was supplemented by using Google Scholar and checking the references of 
relevant articles. Keywords for the database search included variations of Medicaid, 
beneficiary, health status, utilization, and healthcare cost (full search strategy in the 
Appendix, available online). The lead researcher reviewed the articles and extracted data 
during Fall 2016–Spring 2017; any uncertainties about data extraction were brought to the 
coauthors for further review. Titles and abstracts of collected articles were screened to 
exclude those that were (1) review papers, commentaries, editorials, or theses or (2) were not 
about the prevalence or cost burden of noncommunicable chronic diseases among Medicaid 
beneficiaries. The remaining studies underwent full-text review against the following 
exclusion criteria:
1. did not include Medicaid beneficiaries within the age group 18–64 years in the 
analysis (e.g., included only those aged <18 or >64 years) or examined 
exclusively those who were dual eligible (i.e., eligible for both Medicaid and 
Medicare);
2. did not study Medicaid beneficiaries as an independent population group (e.g., 
studied the total population within Medicaid expansion states versus non-
expansion states);
3. did not include disease-specific measures of prevalence or costs; and
4. examined only a specific medication, treatment, or intervention.
Synthesizing Evidence
The prevalence of health conditions and the associated medical costs are presented 
separately. After review, estimates were organized into the following nine disease categories, 
which were created based on their observed representativeness in the included literature: (1) 
heart disease and stroke (including coronary heart disease [CHD], myocardial infarction, 
heart failure [HF] or congestive HF [CHF], pulmonary heart disease, angina, and measures 
of “any heart disease” and cardiovascular disease as a whole); (2) hypertension; (3) 
dyslipidemia (including hyperlipidemia); (4) diabetes; (5) cancer; (6) respiratory illnesses 
(including asthma, chronic obstructive pulmonary disease [COPD], and emphysema); (7) 
mental disorders (including schizophrenia, depression, bipolar disorder, dementia, obsessive 
compulsive disorder, and anxiety disorder); (8) other chronic conditions (including obesity, 
arthritis, renal disease or end-stage renal disease, and peptic ulcer disease); and (9) multiple 
chronic conditions (including prevalence of one or more conditions).
For each cost study, the total (all-cause) medical costs per patient with the disease, the 
disease-related costs, or both are presented when available. Total medical costs per patient 
with the disease captures the all-cause medical costs from any sources, including costs 
resulting from comorbidities or complications and those not directly related to treatment of 
the disease. Disease-related costs include only costs directly related to the treatment of the 
specific disease and therefore do not include other costs that might be incurred for a patient 
with that disease. For example, disease-related costs to treat hypertension might be low, but 
total costs for a hypertensive patient might be much higher because the condition is related 
to costly diseases like CHD or stroke. When available, excess (incremental) costs are noted 
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separately. Excess costs are the difference in total per patient costs between a patient with a 
disease versus a patient without the disease (i.e., total cost per patient with a disease minus 
total cost per patient without the disease). All costs were adjusted to 2015 U.S. dollars using 
the Personal Consumption Expenditures health component price index from the Bureau of 
Economic Analysis.10,11
Many studies explored topics beyond estimating the prevalence or associated costs of 
chronic diseases, such as comparing disease prevalence between Medicaid beneficiaries and 
other groups or examining quality of care or access to care. Although the findings related to 
these topics are also valuable, and some insights from them are included in the discussion 
section, they fall outside the scope of this review and thus these data are not included in the 
results.
RESULTS
In total, 358 articles were collected and screened, leaving 81 articles for full-text review. Of 
these, 29 original research articles12–40 met the selection criteria (Figure 1). Of these, 20 
(69%) examined costs13,17,20–26, 29–37,39,40 and 19 (66%) examined 
prevalence12–20,22,25,27–30,32,33,38,40; ten (34%) included both costs and prevalence.
13,17,20,22,25,29,30,32,33,40
 Among the 29 studies, 17 (59%) examined diabetes; 16 (55%), 
mental disorders; 15 (52%), respiratory illnesses; 15 (52%), heart disease and stroke; 12 
(41%), hypertension; 11 (38%), other chronic conditions; ten (34%), cancer; seven (24%), 
multiple chronic conditions; and six (21%), dyslipidemia. Eleven studies (38%) examined 
only one disease category; 11 (38%) examined two to six; and seven (24%) examined seven 
to nine categories (Appendix Figure 1, available online).
The data used in the 29 studies were from as early as the year 1987 to as late as 2012 (Table 
1). Seventeen studies (59%) used state-specific data from a single state or a combination of 
four or fewer states; the remaining studies used nationally representative data. The most 
common data sources used were state (e.g., North Carolina, California) Medicaid 
administrative and claims data (n=17, 59%); MarketScan (n=4, 14%); the Medical 
Expenditure Panel Survey (n=3, 10%); and the National Health and Nutrition Examination 
Survey (n=3, 10%).
Prevalence estimates for each disease varied by the population group studied (e.g., age 
range, inclusion of dual eligibles); data source type (e.g., claims data, self-reported survey 
data); and the case definitions used to identify diseases. Among the 19 studies exploring 
prevalence, nine examined only those diagnosed with a specific condition (Appendix Table 
2, available online).
Five studies used data from nationally representative surveys and studied the age group 18–
64 years.14,16,18,27,38 These studies were the most comparable for presenting a range of 
prevalence estimates for the population of interest, but differences in their methodologies 
still produced a wide range in estimates for some diseases. One notable difference in 
methodology was whether studies used only self-reported survey responses to measure the 
prevalence of a disease—which misses individuals who are unaware of their condition—or 
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anthropometric and laboratory data, and thus these estimates are presented separately (Table 
2). Other examples of methodologic variation included the inclusion or exclusion of dual 
eligibles and differences in the case definitions used to identify diseases.
Among the aforementioned five studies, the prevalence of having one or more chronic 
conditions (where reported) ranged from 55.7% to 62.1%; of “any heart disease,” from 8.8% 
to 11.8% (one study had estimates for CHD and angina of 5.0% and 2.0%, respectively); of 
stroke, 1.5% to 5.5%; of hypertension, 17.2% to 27.4%; of hyperlipidemia, 16.8% to 23.2%; 
of diabetes, 7.5% to 12.7%; of asthma, 7.8% to 19.3%; of emphysema, 1.6% to 4.8%; of 
depression, 5.0% to 22.3%; and of obesity, 35.3% to 45.2%; one study had an estimate for 
cancer of 9.5% and one had an estimate for arthritis (including joint pain, swelling, or 
stiffness) of 27.7% (Table 2).14,16,18,27,38
The wide range in estimated prevalence of hypertension might be because of variations in 
the methods used to identify hypertensive beneficiaries. Two studies used self-reported data, 
which misses those unaware of their condition, and produced the lower estimates (17.2% 
and 18.0%).27,38 The third and highest estimate (27.4%) came from a study by Decker and 
colleagues,18 who used data with actual blood pressure measurements >140/90 mmHg or the 
use of antihypertensive medications to identify hypertensive beneficiaries, which is a more 
accurate measure. A fourth study by Chang and Davis14 used the same data and method of 
identification for hypertension as Decker and colleagues, but found an improbably low 
estimate of prevalence (9.9%). In addition, Chang and Davis included dual eligibles in their 
analysis whereas Decker and colleagues did not, which should raise the hypertension 
prevalence rather than significantly lower it.14 Therefore, the Chang and Davis estimate was 
treated as an outlier and excluded from the range presented.
Although all asthma prevalence estimates were self-reported, the range in estimates might 
partially be because of differences in the case definitions used to identify asthmatic 
beneficiaries. The lowest estimate (7.8%) was for active asthma, defined as respondents 
reporting they still had asthma or had an asthma attack in the last 12 months,27 whereas the 
other two estimates (15% and 19.3%) were self-reported as having asthma but without a 
time specification.18,38 The wide range in depression prevalence estimates also might have 
resulted from differences in case definitions. Hill et al.27 used the Patient Health 
Questionnaire two-item survey to identify depression and estimated the prevalence as 
16.5%. Chang and Davis14 used the Patient Health Questionnaire nine-item survey and 
defined depression as a score of ten or higher, which is a standard measure of moderate 
depression and produced a comparable estimate (22.3%). Decker and colleagues18 also used 
the Patient Health Questionnaire nine-item survey but did not specify the cut off point used 
to define depression and estimated 5% prevalence. This likely indicates the use of a higher 
cut off point than was used by Chang and Davis—because both studies used the same data 
source—and likely described the prevalence of more severe depression.18
Of the 20 studies exploring costs, 15 included a breakdown of costs by component (e.g., 
outpatient, pharmacy),17,20,22–26,29,30,32–34,36,39,40 and one studied hospital costs only37; the 
remaining four presented total cost without a breakdown of costs by component. Cost 
estimates varied widely for some diseases, which could partially be because of differences in 
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studies’ definitions of included costs and the types of statistical analyses used. Studies varied 
in their inclusion of certain cost components. Most included at least inpatient, outpatient, 
and pharmacy costs, and some included such costs as home health care, skilled and 
intermediate nursing, or long-term care and nursing home costs, which tended to yield 
higher estimates. Five studies employed regression-based methods to compare total costs 
between two or more groups while adjusting for demographic characteristics and 
comorbidities; two compared the costs of patients with a disease to those without the 
disease,20,29 and three compared the costs of patients with a disease between groups with 
varying levels of medication adherence.22,24,40 Estimates from these regression models 
tended to be lower than unadjusted estimates from other studies, after considering 
differences in the cost components included (Appendix Table 3, available online).
One study examined the total healthcare costs per beneficiary among those with just one of 
the nine chronic diseases examined alone (without the presence of any other major chronic 
diseases included in this analysis). This method produced significantly lower cost estimates 
for the studied physical conditions than those estimates that included all beneficiaries with 
the particular disease (including those with other comorbidities) from other studies.23 Cost 
estimates for the physical conditions (e.g., hypertension, CHF, diabetes) examined in this 
study were treated as outliers and excluded from the ranges presented because they are likely 
significant underestimates of a typical patient with one of these conditions, who commonly 
have comorbidities. Cost estimates for mental disorders (e.g., depression, psychosis) from 
this study were included because they were comparable to estimates from other studies and 
it is more reasonable to assume a beneficiary with one of these mental disorders could have 
no other chronic conditions (Table 2; Appendix Table 3, available online).
The estimated total annual cost per beneficiary with CHF in one study ranged from $29,271 
to $38,187 for a medication adherent and nonadherent patient, respectively, after adjusting 
for differences in demographics and comorbidities.22 One study estimated the unadjusted 
total annual cost per patient with HF and HF-related costs were $51,937 and $7,031, 
respectively.33 In this study, the total annual cost per beneficiary with CHD and CHD-related 
costs were estimated at $35,548 and $5,835, respectively.33 Annual hypertension-related 
costs per patient were estimated at $687 in this study, but total annual costs per patient with 
hypertension were estimated at $21,557.33 One study estimated that the emergency 
department, hospitalization, and pharmacy costs of a hypertensive beneficiary depended on 
medication adherence and ranged from $5,458 to $6,038 for patients with high and low 
adherence, respectively, after adjusting for differences in demographics and comorbidities.40 
Annual per patient hyperlipidemia-related costs were estimated in one study at $560,33 and 
in a different study were estimated to range from $2,756 to $3,370 in patients with diabetes.
39
 One study estimated the total annual cost per patient with hyperlipidemia at $18,785.33 
Annual per patient diabetes-related costs were estimated at $3,219 in one study33 and ranged 
up to $4,674 in another study that included skilled and intermediate nursing care and home 
healthcare costs.13 Total annual healthcare costs per beneficiary with diabetes ranged from 
$17,515 (for a medication-adherent patient with hyperlipidemia) in one study to $27,888 in 
another study.33,39
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Estimates of the total healthcare costs per patient diagnosed with cancer in the 6 months 
following diagnosis ranged from $29,384 to $46,194.35,36 Estimates of annual asthma-
related costs ranged from $989 to $1,185 when only claims with asthma as the primary 
diagnosis were included,32,33 and were estimated at $3,069 in another study that included 
claims with asthma as the primary, secondary, or tertiary diagnosis.34 Total medical costs per 
beneficiary with asthma ranged from $5,724 to $9,127.32,33 Two studies examined the 
excess (incremental) cost of a COPD patient compared with a non-COPD patient from a 
matched sample after controlling for demographics and comorbidities and estimated that this 
cost ranged from $2,478 to $2,489.20,29 Estimates for the total cost per patient with COPD 
from the regression models in these two studies ranged from $10,114 (including only 
physician, inpatient, and outpatient costs)29 to $20,900 (including all medical, pharmacy, 
and long-term care costs).20 A separate study estimated the unadjusted average annual cost 
of a COPD patient at $31,753, and estimates for COPD-related costs ranged from $3,968 in 
this study33 to $6,491 in a study that included claims with COPD as the primary, secondary, 
or tertiary diagnosis.34
Annual healthcare costs per patient diagnosed with schizophrenia (or psychosis) were 
estimated at $11,446 (for a patient with psychosis alone without other chronic conditions) in 
one study23 and ranged from $11,972 to $20,585 in another study that compared the costs of 
patients in groups with varying levels of medication adherence, after adjusting for 
covariates.24 A different study estimated the total costs in the 2 years following initiation of 
treatment was $76,679, including nursing home costs.30 One study estimated the annual cost 
of a patient with bipolar disorder at $16,038, 30% of which was estimated as specifically 
bipolar-related costs.25 Estimates for total annual healthcare costs per patient with 
depression ranged from $9,048 (for a patient with depression alone without other chronic 
conditions) to $11,446.23,33 One study estimated that the cost of a beneficiary with one or 
more chronic conditions was $8,881, plus $392 in out-of-pocket costs, and the costs per 
beneficiary with one or more mental disorders was $10,645, plus $475 in out-of-pocket 
costs.17
DISCUSSION
The studies included in this review tended to find a high prevalence of most 
noncommunicable chronic diseases among the Medicaid population. In a subset of studies 
using nationally representative data to examine beneficiaries aged 18–64 years, 55.7% to 
62.1% of these adults had at least one chronic condition,16,18,27 which is higher than 
national estimates of 50% for all adults (which include those aged ≥65 years, who tend to 
have much higher rates of chronic disease).1,2 The difference could be partly because of the 
fact that a segment of the Medicaid population is eligible because of a disability; those in 
this group tend to be in particularly worse health than the general low-income population.
9,28
 However, even studies excluding the disabled or dual eligibles found a relatively high 
prevalence of many chronic diseases compared with other low-income adults.18,27
Medicaid beneficiaries tended to have a high prevalence of heart diseases and related 
conditions.13,15,18 Estimates for hypertension prevalence varied between studies. Regardless, 
all but one of the studies reporting on this condition that examined Medicaid beneficiaries 
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and a comparison group found the prevalence of hypertension to be higher in Medicaid 
beneficiaries.14,15,18,27,38 Hypertension, hyperlipidemia, heart disease, and diabetes were 
common comorbidities in this review.12,19,22,40 Patients with COPD also had high rates of 
hypertension and diabetes.19,20,29,40
Hypertension-related costs were composed mostly of medication costs and were fairly low 
compared with the much higher total cost of a hypertensive patient or a patient with heart 
disease.23,33,40 Similarly, hyperlipidemia-related costs were mostly medication costs and 
were fairly low compared with the total cost of a patient with hyperlipidemia and the cost 
estimates for diabetes or heart disease.13,23,33,39 One study found the total costs per 
beneficiary with HF and CHD to be substantial and that these were the two most costly 
among the diseases they examined, and the total cost of a diabetic beneficiary was found to 
be the fourth highest.33 In separate studies, estimates for the total costs of a patient with 
diabetes with hyperlipidemia and of a patient with CHF were also found to be substantial.
22,39
 These findings highlight the potential value of early identification and treatment of 
hypertension and hyperlipidemia in an attempt to contain later, more expensive costs of their 
sequelae, which is reflected in the literature for cardiovascular disease overall.41–44
In addition to being a costly disease among the estimates in this review, diabetes was also 
the most frequently studied. Diabetes was commonly measured as a comorbidity in studies 
examining only patients with a specific disease and was found to be highly prevalent (20%–
38%) among patients with hypertension, CHF, and COPD.12,19,20,22,29,40 Mental disorders 
were also commonly studied and were prevalent in the Medicaid population. Patients with 
severe mental disorders, such as schizophrenia or bipolar disorder, had high healthcare costs.
17,24–26,30,37
 Clemans-Cope et al.17 found the average annual cost per patient with one or 
more mental disorders to be $11,120 (after summing the separately presented payer costs 
and out-of-pocket costs), well above the average they found of $9,273 per patient with one 
or more chronic conditions overall.
Multiple studies explored Medicaid beneficiaries’ medication adherence and the effect of 
level of adherence on healthcare costs, including studies of patients with schizophrenia, 
hypertension, diabetes, CHF, and hyperlipidemia.22,24,37,39,40 All but one found that better 
adherence was associated with lower total healthcare costs, despite the increase in 
medication costs.22,37,39,40 However, studies consistently found that Medicaid beneficiaries 
tended to have poor medication adherence for their conditions.12,24,30,33,37,39,40 These 
findings suggest that interventions to improve medication adherence for certain diseases 
could be important for controlling Medicaid costs.
The literature on the prevalence and costs of non-communicable chronic diseases among 
adult Medicaid beneficiaries has expanded rapidly in recent years; two thirds of the studies 
included in this review were published in 2010 or later. This expansion could possibly be 
because of an increased focus on the Medicaid program in anticipation of Medicaid 
expansion in 2014 following the 2010 enactment of the Patient Protection and Affordable 
Care Act. However, none of the reviewed studies used data from 2014 or later. The 
expansion of Medicaid has likely produced shifts in the overall demographic composition of 
enrollees to include more childless adults and an increased proportion of males,45,46 and 
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thus it is likely to have changed the average disease burden in the population.14,18,27,47 
Multiple studies compared the then-current (pre-expansion) Medicaid population to those 
potentially eligible under expansion and found then-current beneficiaries to be in similar or 
worse health, suggesting that expansion could shift the Medicaid population to be slightly 
healthier on average.13,17,25 However, the extent of changes to the Medicaid population 
following the Affordable Care Act expansion also depends on the level of outreach and 
potential adverse selection.14,18,27,48–51 The lack of use of post-2014 data in the reviewed 
studies is an evidence gap that should be filled with future research. In addition, possible 
future legislation could further change the design of the Medicaid program, including its 
eligibility requirements,52 which might create additional evidence gaps.
Limitations
The literature had some limitations. Many studies used state-level data, which might limit 
the generalizability of results. States’ Medicaid populations can vary in composition because 
populations differ by region and states have varying eligibility requirements for Medicaid. 
States also vary widely in Medicaid reimbursement rates for services; therefore Medicaid 
expenditure estimates for different states can vary considerably.53 In addition, state Medicaid 
reimbursement rates have varied over time. Studies have found that Medicaid 
reimbursements have generally risen less rapidly with inflation,54 which implies that older 
Medicaid cost studies might yield higher average cost estimates. Older studies might also be 
limited in the applicability of their results because of changes in Medicaid, and the 
healthcare environment overall, over time; some studies used data dating back as far as 
1987, when the healthcare environment likely differed compared with today.
Many studies used claims data, which might under-count the number of patients with certain 
chronic diseases that might not require frequent healthcare visits, such as hypertension, or 
patients who have less frequent access to healthcare services. Further, the studies were 
heterogeneous in their definitions of the Medicaid population and the age group studied. The 
variation in definitions of the population of interest, combined with variations in the 
representativeness of the population (e.g., state-specific versus nationally representative) and 
differences in data sources (e.g., surveys versus claims data), makes it difficult to accurately 
compare some prevalence and cost estimates between studies, and the review’s findings 
should be viewed with this in mind.
This review did not include gray literature, although that literature might also provide 
valuable information. For example, a study from the Urban Institute found prevalence 
estimates for chronic conditions that were similar to those found in this review.9 And a 
working paper for the Agency for Healthcare Research and Quality examined medication 
costs in the Medicaid population.55
CONCLUSIONS
The limitations described above notwithstanding, the present review confirms that the health 
and economic burden of noncommunicable chronic diseases among Medicaid beneficiaries 
has been high. The review suggested that a wide range of prevalence and cost estimates are 
found in the literature. The specific prevalence and cost estimates highlighted here could be 
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used to inform the evaluation of interventions for effectively managing chronic diseases and 
controlling costs in this vulnerable population and for informing future designs of the 
Medicaid program. Future studies using large nationally representative data sets or 
combined state-specific data sources might be needed. Additionally, rigorous analytic 
frameworks, such as economic modeling techniques, should be employed for high-quality 
estimates of the disease prevalence and economic burden among this vulnerable population.
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Figure 1. 
Selecting literature on the prevalence or associated costs of non-communicable chronic 
diseases among Medicaid beneficiaries (2000–2016).
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Table 2
Summary of Selected Prevalence and Cost Estimates for Non-Communicable Chronic Diseases Among 
Medicaid Beneficiaries (2000–2016)
Disease
Prevalence estimates from nationally representative 
data for ages 18–64 years Annual per-patient cost estimatesa
Self-reported alone, % Measured, %
Total cost per patient 
with disease,b $
Disease-related cost 
per patient with 
disease, $
Heart disease and stroke
 Heart disease 8.8–11.8 N/A N/A N/A
  CHD 5.0 N/A 35,548 5,835
  HF/CHF N/A N/A 29,271c–51,937 7,031
  Angina 2.0 N/A N/A N/A
 Stroke 1.5–5.5 N/A N/A N/A
Hypertension 17.2–18 27.4 5,458d–19,821 687
Dyslipidemia
 Hyperlipidemia 16.8 23.2 18,785 560–3,370e
Diabetes 7.7 7.5–12.7 17,515f–27,888 3,219–4,674g
Cancer 9.5 N/A 29,384h–46,194h N/A
 Oral or pharyngeal N/A N/A 34,882 N/A
Respiratory illnesses
 Asthma 7.8i–19.3 N/A 5,724–9,127 989–3,069j
 COPD N/A N/A 10,114k–31,753 3,968–6,491l
 Emphysema 1.6–4.8 N/A N/A N/A
Mental disorders
 Depression 5.0m–22.3 N/A 9,048n–11,231 1,545
 Schizophrenia N/A N/A 11,446n–20,585 N/A
 Bipolar N/A N/A 16,038 4,811o
Other conditions
 Obesity 35.3 42.9–45.2 N/A N/A
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Disease
Prevalence estimates from nationally representative 
data for ages 18–64 years Annual per-patient cost estimatesa
Self-reported alone, % Measured, %
Total cost per patient 
with disease,b $
Disease-related cost 
per patient with 
disease, $
 Arthritis 27.7p N/A N/A N/A
Multiple chronic conditions
 ≥1 chronic conditions 55.7–62.1 N/A 9,273q N/A
 ≥1 mental health conditions N/A N/A 11,120q N/A
aCosts adjusted to 2015 U.S. dollars using the Personal Consumption Expenditures health component price index. Excludes 2-year cost estimates 
from two studies, estimates from one study examining only hospital costs, and estimates from one study examining only ambulatory cancer costs. 
Six-month cancer cost estimates included but noted.
b
Estimates for physical conditions from one study reporting the total cost per patient with the disease alone (without the presence of other major 
chronic conditions) were treated as outliers and excluded.
c
For a medication-adherent patient. Estimate from a regression-adjusted model comparing adherent and nonadherent patients.
d
Estimate for a medication-adherent patient. Includes only emergency department visits, hospitalizations, and medication costs. Estimate from a 
regression-adjusted model comparing adherent and nonadherent patients.
e
Estimate for a medication-nonadherent diabetes patient with hyperlipidemia.
f
Estimate for a diabetes patient with hyperlipidemia who is adherent to medication.
g
Includes skilled and intermediate nursing care.
h
Total costs per cancer patient in the 6 months following initiation of treatment.
i
“Active asthma” defined as respondents reporting they still had asthma or had an asthma attack in the past 12 months.
j
Includes claims with asthma as the primary, secondary, or tertiary diagnosis as asthma-related costs.
k
Includes only physician office, inpatient, and outpatient costs. Estimate from a regression-adjusted model comparing total cost per COPD patient 
with a matched non-COPD cohort.
l
Includes claims with COPD as the primary, secondary, or tertiary diagnosis as COPD-related costs.
m
Patient Health Questionnaire nine-item survey cut off point not specified; likely a measure of more severe depression.
nCost of a patient with the condition alone (without the presence of other major chronic conditions).
o
Defined as 30% of total costs of a bipolar patient in original study; 30% of the $16,038 total cost estimate=$4,811.
p
Includes respondents with pain, aching, stiffness, or swelling around the joint in the past 12 months.
qSum of the separately presented Medicaid costs and out-of-pocket costs.
CHD, coronary heart disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; HF, heart failure; N/A, not applicable.
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